Welcome to our dedicated page for Smith & Nephew Plc SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Smith & Nephew Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Smith & Nephew Plc's regulatory disclosures and financial reporting.
Cevian Capital II GP LTD filed Amendment No. 4 to its Schedule 13D on Smith & Nephew plc, reporting beneficial ownership of 81,687,136 ordinary shares, equal to 9.6% of the outstanding shares. Cevian has sole voting and dispositive power over this entire stake.
Cevian states it bought these shares for the Cevian funds for total consideration of about USD $1,095,708,998, funding the purchases from the funds’ general working capital and paying in British pounds, using an exchange rate of USD $1.32385 per GBP 1.00. The 9.6% figure is based on 849,889,305 ordinary shares outstanding as of February 28, 2026, as reported by the issuer on Form 6-K filed on March 2, 2026.
Smith & Nephew plc submitted a Form 6-K to inform investors that its 2025 Annual Report and related shareholder documents are now available. The company has published the 2025 Annual Report, the Notice of the 2026 Annual General Meeting, the Form of Proxy for the 2026 AGM, and proposed new Articles of Association.
The 2025 Annual Report on Form 20-F was also filed with the SEC on the same day, and all documents are accessible via the UK National Storage Mechanism and the company’s investor relations website.
Smith & Nephew plc filed a Form 6-K stating that it has sent its annual report for fiscal year 2025 to shareholders. The report for the year ended 31 December 2025 is attached as Exhibit 99.1. This filing is primarily administrative, forwarding the full annual report to investors.
Smith & Nephew delivered stronger full-year 2025 results, with revenue rising to $6,164m from $5,810m and operating profit increasing to $794m from $657m. Attributable profit grew to $625m, lifting basic earnings per share to 72.1¢ from 47.2¢.
Growth was broad-based: Orthopaedics revenue reached $2,437m, Sports Medicine & ENT $1,934m, and Advanced Wound Management $1,793m. Established Markets generated $5,161m of revenue and Emerging Markets $1,003m, with US revenue at $3,306m.
Cash generation was robust, with net cash from operating activities of $1,285m. The company invested $433m in capital expenditure and paid equity dividends of $330m, while also spending $502m on share repurchases. Year-end cash and cash equivalents were $553m, and net debt excluding leases was $2,543m.
Deloitte issued unqualified opinions on both the financial statements and internal control over financial reporting. A key audit focus was the valuation of the excess and obsolescence provision for US orthopaedics inventory, reflecting judgement around future product demand.
Smith+Nephew plc reports that its Chief Executive Officer, Deepak Nath, will join the Board of Reckitt Benckiser Group plc as an independent Non-Executive Director with effect from 1 April 2026. The appointment is disclosed in line with UK Listing Rule 6.4.9R(2).
Smith+Nephew is a global medical technology business focused on repairing, regenerating and replacing soft and hard tissue. It employs around 17,000 people, operates in more than 100 countries and generated annual sales of $6.2 billion in 2025 across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Smith & Nephew plc has updated investors on its voting rights and share capital. As at 28 February 2026, the company had 877,724,845 ordinary shares of US20¢ each in issue, including 27,835,540 shares held in treasury. Because treasury shares do not carry voting rights, shareholders have a total of 849,889,305 voting shares to use as the denominator when assessing whether they must notify the regulator of their holdings or changes in their stake.
Smith+Nephew delivered a strong 2025, with revenue rising to $6,164 million from $5,810 million, an underlying growth of 5.3%. Trading profit grew 15.5% to $1,211 million, lifting the trading margin to 19.7%, while operating profit increased 20.7% to $794 million.
Earnings improved sharply, with EPS up 52.8% to 72.1¢ and EPSA up 21.0% to 102.0¢. Free cash flow jumped 52.5% to $840 million, supporting a $500 million share buyback and a 4.3% dividend increase to 39.1¢ per share.
The company completed its 12-Point Plan, expanded adjusted ROIC to 8.3%, and launched its new RISE strategy with 2028 targets including 6–7% organic revenue CAGR and free cash flow above $1 billion. For 2026, it targets around 6% underlying revenue growth, trading profit of about $1.3 billion, free cash flow around $800 million, and adjusted ROIC above 10%, alongside integrating the $225 million Integrity Orthopaedics acquisition.
Smith+Nephew reported stronger fourth quarter and full-year 2025 results, showing broad-based growth and better profitability. Full-year revenue reached $6,164 million, up 6.1% from 2024, with underlying revenue growth of 5.3% and all three business units above 5% underlying growth.
Trading profit rose to $1,211 million, up 15.5%, lifting the trading margin to 19.7%. Basic EPS increased to 72.1 cents, while adjusted EPS climbed 21.0% to 102.0 cents. Free cash flow improved sharply to $840 million, helped by better working capital, and adjusted ROIC rose to 8.3%.
The company returned $500 million through share buybacks and raised the total 2025 dividend by 4.3% to 39.1 cents per share. For 2026, management targets around 6% underlying revenue growth, trading profit of about $1.3 billion including the Integrity Orthopaedics deal, around $800 million free cash flow and adjusted ROIC above 10%.
Smith & Nephew plc filed a Form 6-K providing a block listing six monthly return for several employee share schemes for the period from 1 August 2025 to 31 January 2026.
The filing shows no changes in unallotted securities for the Global Share Plan 2010, the 2012 and 2022 ShareSave and International ShareSave plans. Under the Global Share Plan 2020, 14,695 securities were issued or allotted during the period, reducing the unallotted balance under that scheme to 388,563 shares.
Smith & Nephew plc has updated its voting rights and share capital. As at 31 January 2026, the company’s total issued share capital comprises 877,724,845 ordinary shares of US20¢ each, including 27,912,707 ordinary shares held in treasury.
Because treasury shares do not carry voting rights, the company’s issued share capital with voting rights consists of 849,812,138 ordinary shares, each carrying one vote. Shareholders are advised to use this voting share figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.